Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2, Randomized, Double-Blind, Crossover Study to Examine the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Single Doses of TD-4208 in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease

Thirty-two subjects diagnosed with COPD were enrolled, received each study treatment and completed the follow-up assessments. During each of the four study periods, subjects were admitted to the clinic on Day -1 and housed overnight until after the last spirometry measurement. Serial pulmonary function tests were performed and PK (pharmacokinetics) samples collected up to 25 hours. Subjects were discharged from the clinic on Day 2 after evaluations.

Study Overview

• Status: Completed
• Conditions: Chronic Obstructive Pulmonary Disease, COPD
• Intervention / Treatment: Drug: Placebo; Drug: TD-4208 700 μg; Drug: TD-4208 350 μg; Drug: Ipratropium 500 μg

Detailed Description

Subjects were assigned to one of the 4-treatment sequence groups presented in the table above according to a randomization schedule supplied by the Sponsor before study initiation. The randomization scheme did not include assignments for replacement subjects.

Subjects reported to their respective clinical research unit (CRU) on Admission/Day -1 for pre-randomization procedures and confirmation of eligibility (and continued eligibility for Periods 2 to 4). The unblinded pharmacist prepared and dispensed the nebulizers, according to the randomization schedule for each of the 4 periods. Dosing occurred in the morning, generally between 7 am and 9 am. For Periods 2 to 4, dosing occurred within ±30 minutes of the dosing time established in Period 1.

Study drug was administered in the respective CRU under the supervision of study personnel. Single doses of TD-4208, ipratropium bromide, and placebo were administered in the clinical research unit (CRU) under the supervision of study personnel. Care was taken to avoid eye contact with study drugs. Residual drug solution remaining in the nebulizer (ie, in mL) was measured and recorded.

The investigator or designee was responsible for maintaining accountability records for all study drug(s) in accordance with applicable government regulations and study procedures.

The accountability record included entries for receipt, distribution or dispensing, and destruction of the material(s). Unused and expired study drugs were to be disposed of in accordance with written instructions from the Sponsor.

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Phase 2

Contacts and Locations

Study Locations

• New Zealand
  • Wellington, New Zealand, 6021
    • P3 Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 75 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of moderate stable Chronic Obstructive Pulmonary.
• Disease with FEV1/FVC <0.7 at screening.
• Woman of non-childbearing potential.
• Female participants of childbearing potential must test negative for pregnancy and must be using a highly effective method of birth control during the study and for at least 1 month after completion of study dosing.
• Female participants must not be breastfeeding.
• Men must agree to use a highly effective method of birth control with partners of childbearing potential during the study and for 1 month after completion of study dosing.
• Current or past smoking history >10 pack-years.
• Must be capable of performing reproducible spirometry maneuvers.

Exclusion Criteria:

• History of significant respiratory disease other than COPD, and/ or requires daily long-term oxygen therapy.
• Exacerbation of COPD, lung infection within 6 weeks prior to study.
• Start of or change in dose of COPD treatment 4 weeks before study.
• Daily using of maintenance systemic/inhaled corticosteroids (>1000 microgram of fluticasone propionate equivalent or >5 mg prednisone).
• Use of bronchodilators or medication for the treatment of COPD, aspirin, anti-inflammatories for a specific time, prior to the first dose or is not willing to abstain from their use for the specified time periods prior to study dose administration.
• Symptomatic prostrate hypertrophy, bladder neck obstruction, active cancer, narrow angle glaucoma.
• Clinical significant hypersensitivity to medications.
• Participants have an uncontrolled hematologic, immunologic, renal, neurologic, hepatic, endocrine or other disease that may place participant at risk.
• Cerebrovascular, cardiovascular disease or abnormal ECG.
• History of drug or alcohol abuse.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: QUADRUPLE

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Sequence 1; Period 1 = Placebo; Period 2 = TD-4208 700 μg; Period 3 = TD-4208 350 μg; Period 4 = Ipratropium 500 μg	Drug: Placebo; Drug: TD-4208 700 μg; Other Names: Revefenacin; Drug: TD-4208 350 μg; Other Names: Revefenacin; Drug: Ipratropium 500 μg
EXPERIMENTAL: Sequence 2; Period 1 = TD-4208 700 μg; Period 2 = Ipratropium 500 μg; Period 3 = Placebo; Period 4 = TD-4208 350 μg	Drug: Placebo; Drug: TD-4208 700 μg; Other Names: Revefenacin; Drug: TD-4208 350 μg; Other Names: Revefenacin; Drug: Ipratropium 500 μg
EXPERIMENTAL: Sequence 3; Period 1 = TD-4208 350 μg; Period 2 = Placebo; Period 3 = Ipratropium 500 μg; Period 4 = TD-4208 700 μg	Drug: Placebo; Drug: TD-4208 700 μg; Other Names: Revefenacin; Drug: TD-4208 350 μg; Other Names: Revefenacin; Drug: Ipratropium 500 μg
EXPERIMENTAL: Sequence 4; Period 1 = Ipratropium 500 μg; Period 2 = TD-4208 350 μg; Period 3 = TD-4208 700 μg; Period 4 = Placebo	Drug: Placebo; Drug: TD-4208 700 μg; Other Names: Revefenacin; Drug: TD-4208 350 μg; Other Names: Revefenacin; Drug: Ipratropium 500 μg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Peak Forced Expiratory Volume in One Second (FEV1) Relative to Baseline	From predose to 25 hours postdose

Secondary Outcome Measures

Outcome Measure	Time Frame
Area Under the FEV1 vs. Time Curve, Time-matched Difference From Placebo	12 hr and 24 hr
Area Under the FEV1 vs. Peak FEV1, Time-matched Difference From Placebo	12 hr and 24 hr
Peak Expiratory Flow Rate (PEFR) From 25% to 75% of Vital Capacity (FEF25-75), as Related to FEV1	12hr and 24hr
Forced Expiratory Flow From 25% to 75% of Vital Capacity (FEF25-75), as Related to FEV1	12hr and 24hr
Forced Vital Capacity (FVC)	From predose to 25 hours postdose
Area Under the Forced Vital Capacity (FVC) vs. Time Curve	0-24 hours

Collaborators and Investigators

• Sponsor: Mylan Inc.
• Collaborators: Theravance Biopharma

Publications and helpful links

General Publications

• Lo A, Borin MT, Bourdet DL. Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease. Clin Pharmacokinet. 2021 Mar;60(3):391-401. doi: 10.1007/s40262-020-00938-3.

Study record dates

Study Major Dates

• Study Start: May 1, 2011
• Primary Completion (ACTUAL): October 1, 2011
• Study Completion (ACTUAL): October 1, 2011

Study Registration Dates

• First Submitted: January 20, 2017
• First Submitted That Met QC Criteria: February 21, 2017
• First Posted (ACTUAL): February 24, 2017

Study Record Updates

• Last Update Posted (ACTUAL): February 24, 2022
• Last Update Submitted That Met QC Criteria: February 22, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Keywords: Chronic Obstructive Pulmonary Disease, COPD
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Cholinergic Antagonists; Cholinergic Agents; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Ipratropium
• Other Study ID Numbers: 0059; ACTRN12611000482965 (REGISTRY: ANZCTR); U1111-1120-8290 (OTHER: Universal Trial Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO